Patent details

LUC00242 Product Name: Odévixibat et ses dérivés pharmaceutiquement acceptables (Bylvay)

Basic Information

Publication number:
LUC00242
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP181798844
Legal Status:
Inactive
Application number:
LUC00242
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/21/1566
Marketing Authorization Type:
Marketing Authorization Date:
19/07/2021
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
30/11/2021
First Marketing Authorization date:
19/07/2021
Grant date:
03/02/2025
Activation date:
Publication date:
30/11/2021
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
19/07/2036
SPC Extension Expiration:
19/07/2036
Rejection date:
Withdrawal date:

Owner

From:
30/11/2021
 
 

Name:
Albireo AB
Address:
Arvid Wallgrens Backe 20, 413 46 Göteborg, Sweden (SE)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
30/11/2021
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2021/13
Publication date:
02/12/2021
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2025/04
Publication date:
04/03/2025
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
01/12/2031
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
30/11/2021 Application Form 3
30/11/2021 Outgoing Correspondence 1
30/11/2021 Marketing authorization 3
30/11/2021 MA publication 9
30/11/2021 Summary of the product caracteristics 45
30/11/2021 Publication 1
03/02/2025 Publication 1
03/02/2025 Certificate 1
03/02/2025 Outgoing Correspondence 1